(+)-Vincristine
Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type
Explore 23 assets in Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type →Floatz Rating
B60/100
Confidence
Indicative
Sponsor
Li Zhiming
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
45Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05422066CT.gov Selinexor Plus R-CHOP in High-risk GCB-subtype Diffuse Large B-Cell Lymphoma | — | Recruiting | — | — | — |
NCT04933617CT.gov Copanlisib With Dose-Adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell Lymphomas | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| (+)-Vincristine (this asset) | Li Zhiming | P2 | B · 60 |
| Adriamycin | Li Zhiming | P2/3 | BB |
| Prednisone | National Cancer Institute (NCI) | P2/3 | BB |
| Rituximab | Mayo Clinic | P2/3 | BB |
| Cyclophosphamide | Li Zhiming | P2/3 | BB |
| Vincristine Sulfate | National Cancer Institute (NCI) | P2/3 | BB |
| Azacitidine | National Cancer Institute (NCI) | P2/3 | B |
| Recombinant Human Hyaluronidase | National Cancer Institute (NCI) | P2/3 | B |
| Selinexor | Li Zhiming | P2 | CCC |
+15 more in the Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type cohort
Other indications for (+)-Vincristine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Mycosis Fungoides | — | P4 | BBB · 78 |
| Anaplastic Large Cell Lymphoma | — | P4 | BBB · 78 |
| Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | — | P4 | BBB · 77 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. (+)-Vincristine in Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/vincristine-diffuse-large-b-cell-lymphoma-germinal-center-b-cell-type
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →